Cargando…

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD

Adult T‐cell acute lymphoblastic leukemia (T‐ALL) is a heterogeneous group of acute leukemias that account for about one third of all cases of Philadelphia chromosome (Ph)‐negative ALL. Recently, a molecular classifier using the mutational status of NOTCH1, FBXW7, RAS, and PTEN (NFRP) has been shown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakhdari, Ali, Thakral, Beenu, Loghavi, Sanam, Kanagal‐Shamanna, Rashmi, Yin, C. Cameron, Zuo, Zhuang, Routbort, Mark J., Luthra, Rajyalakshmi, Medeiros, L. Jeffrey, Wang, Sa A., Patel, Keyur P., Ok, Chi Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997098/ https://www.ncbi.nlm.nih.gov/pubmed/31804006 http://dx.doi.org/10.1002/cam4.2757

Ejemplares similares

P729: LANDSCAPE OF GERMLINE PATHOGENIC/ LIKELY PATHOGENIC MUTATIONS INVOLVING DNA REPAIR GENES IN SOLID TUMOR PATIENTS WITH ANTECEDENT OR SUBSEQUENT MYELOID NEOPLASMS
por: Hein, Kimberly, et al.
Publicado: (2023)

Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing
por: Quesada, Andrés E., et al.
Publicado: (2018)

Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
por: Zuo, Zhuang, et al.
Publicado: (2022)

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2017)

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
por: Ok, Chi Young, et al.
Publicado: (2019)

An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma
por: Boddu, Prajwal, et al.
Publicado: (2017)

Hyper-CVAD-Based Stem Cell Microtransplant as Post-Remission Therapy in Acute Lymphoblastic Leukemia
por: Cai, Bo, et al.
Publicado: (2022)

Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen
por: Ryu, Il Hwan, et al.
Publicado: (2015)

Complete remission with romidepsin in a patient with T‐cell acute lymphoblastic leukemia refractory to induction hyper‐CVAD
por: Brunvand, Mark W., et al.
Publicado: (2017)

Retinal and Preretinal Hemorrhages in a Patient Receiving Hyper-CVAD Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
por: Peddada, Krishi, et al.
Publicado: (2018)

P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES
por: Atluri, Himachandana, et al.
Publicado: (2023)

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
por: Tashakori, Mehrnoosh, et al.
Publicado: (2022)

Effectiveness of modified hyper‐CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience
por: Jalaeikhoo, Hasan, et al.
Publicado: (2018)

Cytarabine Induced Acute Cerebellar Syndrome during Hyper-CVAD Treatment for B-Cell Acute Lymphoblastic Leukemia
por: Tran, Phu Ngoc, et al.
Publicado: (2017)

Beyond Hyper-CVAD in ALL: Highlights From SOHO 2021
Publicado: (2022)

Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report
por: Huang, Lanshan, et al.
Publicado: (2016)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
por: Kantarjian, Hagop, et al.
Publicado: (2023)

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
por: Ok, Chi Young, et al.
Publicado: (2015)

Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study
por: Malakoutikhah, Zahra, et al.
Publicado: (2023)

Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features
por: Shuai, Wen, et al.
Publicado: (2020)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014)

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors
por: Mehrotra, Meenakshi, et al.
Publicado: (2017)

Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era
por: Montes-Moreno, Santiago, et al.
Publicado: (2018)

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2016)

Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy
por: Quesada, Andrés E., et al.
Publicado: (2021)

A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience
por: Li, Chun, et al.
Publicado: (2020)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

Clinical outcomes of patients with acute lymphoblastic leukemia receiving the hyper-CVAD regimen and assessment of the risk of hepatitis flares due to hepatitis B virus reactivation after chemotherapy
por: Law, Man Fai, et al.
Publicado: (2021)

Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray
por: Chen, Hui, et al.
Publicado: (2017)

B‐lymphoblastic leukemia with Burkitt‐like morphology and aberrant myeloperoxidase expression: A diagnostic conundrum
por: Nahmod, Karen A., et al.
Publicado: (2022)

P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY
por: Short, Nicholas, et al.
Publicado: (2023)

The Use of R-Hyper-CVAD in a Rare Case of Primary Bone Marrow Diffuse Large B-Cell Lymphoma
por: Reed, Allison, et al.
Publicado: (2019)

Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience
por: El Hussein, Siba, et al.
Publicado: (2020)

Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience
por: Sonnevi, Kristina, et al.
Publicado: (2021)

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
por: Hong, Junshik, et al.
Publicado: (2015)

Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.
por: Abla, Dima, et al.
Publicado: (2022)

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse
por: Samra, Bachar, et al.
Publicado: (2021)

A Rare Case of p190 BCR-ABL B-cell Acute Lymphocytic Leukemia With Excellent Response to Hyper-CVAD and Ponatinib
por: DeRon, Nathan, et al.
Publicado: (2022)

Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features
por: Khanlari, Mahsa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gtk21gk1k9bq0avu6u0e31qrti